Pfizer has the experience and resources to develop and manufacture biosimilar medicines
Biosimilar medicines are part of the future of biologic treatment, and Pfizer Biosimilars is committed to working at every level to make the full potential of biosimilar medicines a reality across the communities we serve.
For 30 years, Pfizer has dedicated significant resources to providing high-quality biologic medicines and selecting exceptional supply partners, with a development program supported by robust clinical and analytical data. Pfizer continues building on this through Pfizer Biosimilars, leveraging nearly 10 years of additional experience with biosimilars outside the United States.
Expertise rooted in the heritage and global presence
of Pfizer
- Developing and delivering quality medicines around the world
- Experience in biologics (originator and biosimilar) and small molecules (branded and off-patent generic)
- Global supply network to provide fast and flexible solutions across the full manufacturing and supply-chain spectrum
Pfizer brings therapies to patients around the world, in many therapeutic areas, such as
Endocrinology Neurology Immunology and Inflammation Oncology Hematology
Invested in the future of biosimilars
As of May 2019, with 4 biosimilars marketed outside the United States, 3 in market in the United States, 2 in late-stage development, and 2 under review with the FDA, Pfizer is firmly committed to the future of biosimilars.
